By Michael Susin
GSK said it has sold a stake in Haleon valued around 978 million pounds ($1.24 billion), reducing its stake in the consumer-healthcare business to around 4.2%.
The British pharmaceutical giant said Wednesday that it has sold 300 million Haleon shares at an offer price of 326 pence a share. This represents a discount of 2.3% from Tuesday’s closing price of 333.6 pence prior to the announcement.
U.S. pharma giant Pfizer also holds a 32% stake in Haleon, which was spun out of GSK and Pfizer’s consumer-healthcare business.
Write to Michael Susin at michael.susin@wsj.com
